Pharma Commercial Mock
← All views·CI feed·API docs
AASCO
Meeting Library
ESMO Congress 2026 · Barcelona, Spain
54 shown of 2,268 total abstracts
  1. Abstract 92602026-09-04 · 19:00 CT · E450
    IMpower-292: Tecentriq (atezolizumab) maintenance in NSCLC
    S. Antonia, S. Peters · Dana-Farber Cancer Institute
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  2. Abstract 91652026-09-05 · 21:15 CT · E450
    DESTINY-Breast-281: Enhertu (trastuzumab deruxtecan) 1L in NSCLC
    S. Modi, E. Winer · MD Anderson Cancer Center
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  3. Abstract 98552026-09-03 · 14:30 CT · Hall B1
    Real-world effectiveness of Enhertu vs standard of care in NSCLC
    F. Andre, S. Modi · Johns Hopkins Kimmel Cancer Center
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  4. Abstract 90922026-09-02 · 20:15 CT · Hall B1
    Long-term follow-up of Imfinzi 1L for SCLC: PACIFIC-676
    L. Paz-Ares, C. Robert, C. Saura, et al. · Princess Margaret Cancer Centre
    Rapid Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  5. Abstract 98872026-09-05 · 20:45 CT · Hall B1
    Biomarker subgroup analysis of Opdivo in NSCLC (the CheckMate-803 study)
    G. Curigliano, M. Krop, C. Saura, et al. · National Cancer Center Japan
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  6. Abstract 95882026-09-04 · 20:15 CT · S406
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-23
    T. Mok, H. Rugo, E. Winer, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  7. Abstract 98492026-09-04 · 20:45 CT · E450
    DESTINY-Breast-242: Enhertu (trastuzumab deruxtecan) 3L+ in NSCLC
    H. Rugo, S. Peters, C. Robert, et al. · Peter MacCallum Cancer Centre
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  8. Abstract 97742026-09-02 · 19:45 CT · Hall B1
    Biomarker subgroup analysis of Imfinzi in NSCLC (the PACIFIC-293 study)
    S. Modi, M. Reck, J. Brahmer · Karolinska Institute
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  9. Abstract 93382026-09-01 · 16:30 CT · Arie Crown Theater
    Quality of life outcomes with Enhertu in patients with NSCLC
    J. Cortes, E. Winer, J. Brahmer, et al. · Princess Margaret Cancer Centre
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  10. Abstract 93952026-09-02 · 21:15 CT · S100A
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-545 study)
    P. Schmid, C. Robert, S. Peters, et al. · Vall d'Hebron Institute of Oncology
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  11. Abstract 96032026-09-02 · 14:00 CT · Arie Crown Theater
    Quality of life outcomes with Tagrisso in patients with NSCLC
    S. Peters, T. Mok, A. Spira, et al. · Mayo Clinic
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  12. Abstract 90152026-09-02 · 15:00 CT · S100A
    Long-term follow-up of Imfinzi adjuvant for NSCLC: PACIFIC-781
    C. Robert, L. Paz-Ares, T. Mok, et al. · Peter MacCallum Cancer Centre
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  13. Abstract 93162026-09-03 · 16:45 CT · Hall B1
    Long-term follow-up of Enhertu 1L for NSCLC: DESTINY-Breast-483
    S. Antonia, J. Brahmer, S. Peters, et al. · Johns Hopkins Kimmel Cancer Center
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  14. Abstract 99062026-09-03 · 19:00 CT · Hall B1
    Long-term follow-up of Tagrisso 3L+ for NSCLC: FLAURA-350
    S. Modi, A. Spira, J. Cortes, et al. · Cleveland Clinic
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  15. Abstract 97542026-09-05 · 14:30 CT · E450
    Quality of life outcomes with Keytruda in patients with NSCLC
    M.C. Garassino, E. Winer · Memorial Sloan Kettering Cancer Center
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  16. Abstract 90952026-09-04 · 19:00 CT · S100A
    Long-term follow-up of Tecentriq adjuvant for NSCLC: IMpower-646
    T. Mok, S. Modi · Dana-Farber Cancer Institute
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  17. Abstract 95242026-09-03 · 19:15 CT · E450
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-658 study)
    M. Reck, J. Cortes · Stanford Cancer Institute
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  18. Abstract 98512026-09-04 · 14:30 CT · S406
    Long-term follow-up of Opdivo 1L for NSCLC: CheckMate-820
    C. Saura, J. Brahmer, M. Krop · Institut Gustave Roussy
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  19. Abstract 96682026-09-04 · 20:30 CT · S406
    Biomarker subgroup analysis of Enhertu in NSCLC (the DESTINY-Breast-917 study)
    J. Cortes, N. Rizvi, L. Paz-Ares, et al. · National Cancer Center Japan
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  20. Abstract 90882026-09-01 · 19:00 CT · S100A
    CheckMate-802: Opdivo (nivolumab) maintenance in NSCLC
    S. Tolaney, C. Robert · University of Chicago
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  21. Abstract 99012026-09-03 · 20:45 CT · E450
    Real-world effectiveness of Imfinzi vs standard of care in NSCLC
    C. Saura, J. Brahmer, F. Andre, et al. · Vall d'Hebron Institute of Oncology
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  22. Abstract 93272026-09-04 · 21:45 CT · E450
    Quality of life outcomes with Imfinzi in patients with NSCLC
    J. Brahmer, J. Cortes, L. Paz-Ares, et al. · Peter MacCallum Cancer Centre
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  23. Abstract 93832026-09-01 · 19:30 CT · S406
    KEYNOTE-386: Keytruda (pembrolizumab) adjuvant in SCLC
    J. Brahmer, M.C. Garassino, L. Paz-Ares, et al. · Massachusetts General Hospital
    Rapid Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  24. Abstract 91602026-09-04 · 19:00 CT · Hall B1
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-929 study)
    M.C. Garassino, A. Spira, L. Paz-Ares · Princess Margaret Cancer Centre
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  25. Abstract 96942026-09-03 · 21:30 CT · Hall B1
    Biomarker subgroup analysis of Keytruda in NSCLC (the KEYNOTE-733 study)
    S. Tolaney, T. Mok, J. Brahmer, et al. · Peter MacCallum Cancer Centre
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  26. Abstract 98622026-09-05 · 21:30 CT · Hall B1
    Long-term follow-up of Tecentriq adjuvant for NSCLC: IMpower-807
    J. Cortes, N. Rizvi · Stanford Cancer Institute
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  27. Abstract 90552026-09-03 · 13:30 CT · Arie Crown Theater
    FLAURA-154: Tagrisso (osimertinib) 1L in NSCLC
    H. Borghaei, L. Paz-Ares, P. Schmid, et al. · Massachusetts General Hospital
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  28. Abstract 92612026-09-04 · 21:30 CT · S100A
    Real-world effectiveness of Keytruda vs standard of care in NSCLC
    F. Andre, J. Cortes · Dana-Farber Cancer Institute
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  29. Abstract 94862026-09-01 · 18:00 CT · S100A
    Real-world effectiveness of Tagrisso vs standard of care in NSCLC
    J. Brahmer, S. Peters · Dana-Farber Cancer Institute
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  30. Abstract 91872026-09-02 · 16:30 CT · S406
    Biomarker subgroup analysis of Imfinzi in SCLC (the PACIFIC-376 study)
    A. Spira, F. Andre, M. Reck, et al. · Institut Gustave Roussy
    Rapid Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  31. Abstract 90822026-09-05 · 16:00 CT · S406
    Enhertu plus chemotherapy in previously untreated NSCLC: updated analysis from DESTINY-Breast-404
    H. Borghaei, J. Cortes · Chinese University of Hong Kong
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  32. Abstract 90082026-09-05 · 21:30 CT · E450
    FLAURA-484: Tagrisso (osimertinib) adjuvant in NSCLC
    S. Tolaney, M. Krop, L. Paz-Ares · Mayo Clinic
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  33. Abstract 92022026-09-03 · 15:00 CT · Hall B1
    IMpower-562: Tecentriq (atezolizumab) 2L in NSCLC
    L. Paz-Ares, H. Borghaei, R. Herbst, et al. · Cleveland Clinic
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  34. Abstract 93752026-09-05 · 13:00 CT · Hall B1
    Long-term follow-up of Imfinzi neoadjuvant for NSCLC: PACIFIC-266
    L. Paz-Ares, H. Rugo · Cleveland Clinic
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  35. Abstract 93812026-09-03 · 13:45 CT · S406
    Long-term follow-up of Enhertu 2L for NSCLC: DESTINY-Breast-408
    G. Curigliano, S. Modi · Cleveland Clinic
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  36. Abstract 93862026-09-03 · 14:30 CT · S406
    Long-term follow-up of Tecentriq neoadjuvant for NSCLC: IMpower-325
    S. Antonia, H. Borghaei, M.C. Garassino · Dana-Farber Cancer Institute
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  37. Abstract 92732026-09-04 · 16:45 CT · Hall B1
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-245 study)
    J. Cortes, L. Paz-Ares, H. Rugo · MD Anderson Cancer Center
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  38. Abstract 96392026-09-03 · 19:15 CT · S100A
    Biomarker subgroup analysis of Enhertu in NSCLC (the DESTINY-Breast-252 study)
    P. Schmid, H. Borghaei, T. Mok, et al. · National Cancer Center Japan
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  39. Abstract 91862026-09-01 · 15:00 CT · E450
    DESTINY-Breast-817: Enhertu (trastuzumab deruxtecan) 3L+ in NSCLC
    M. Krop, J. Cortes, P. Schmid, et al. · Stanford Cancer Institute
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  40. Abstract 99132026-09-05 · 14:15 CT · S406
    Long-term follow-up of Tagrisso 2L for NSCLC: FLAURA-726
    N. Rizvi, H. Borghaei · Vall d'Hebron Institute of Oncology
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  41. Abstract 90382026-09-01 · 13:00 CT · Hall B1
    Long-term follow-up of Enhertu adjuvant for NSCLC: DESTINY-Breast-304
    S. Tolaney, M. Reck · Institut Gustave Roussy
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  42. Abstract 93062026-09-05 · 21:45 CT · Hall B1
    Long-term follow-up of Imfinzi maintenance for SCLC: PACIFIC-185
    S. Peters, R. Herbst, T. Mok, et al. · Institut Gustave Roussy
    Rapid Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  43. Abstract 97832026-09-03 · 15:30 CT · S100A
    Long-term follow-up of Tagrisso 1L for NSCLC: FLAURA-795
    J. Cortes, F. Andre, S. Antonia, et al. · Johns Hopkins Kimmel Cancer Center
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  44. Abstract 99762026-09-03 · 15:45 CT · Arie Crown Theater
    Long-term follow-up of Keytruda 2L for SCLC: KEYNOTE-587
    J. Brahmer, L. Paz-Ares, M. Reck, et al. · Institut Gustave Roussy
    Rapid Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  45. Abstract 98342026-09-05 · 14:15 CT · Arie Crown Theater
    Tecentriq plus chemotherapy in previously untreated NSCLC: updated analysis from IMpower-319
    F. Andre, T. Mok, S. Peters, et al. · Peter MacCallum Cancer Centre
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  46. Abstract 90312026-09-03 · 18:30 CT · Hall B1
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-589
    S. Antonia, M. Krop, A. Spira · Institut Gustave Roussy
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  47. Abstract 98282026-09-01 · 14:45 CT · Hall B1
    Quality of life outcomes with Imfinzi in patients with SCLC
    M. Reck, G. Curigliano, C. Saura, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Rapid Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  48. Abstract 91472026-09-05 · 20:00 CT · Arie Crown Theater
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-773
    T. Mok, H. Borghaei · Karolinska Institute
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  49. Abstract 95262026-09-02 · 13:00 CT · E450
    Biomarker subgroup analysis of Tecentriq in NSCLC (the IMpower-552 study)
    M. Reck, S. Peters · Stanford Cancer Institute
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  50. Abstract 95932026-09-03 · 14:30 CT · S406
    Biomarker subgroup analysis of Tecentriq in NSCLC (the IMpower-347 study)
    C. Robert, F. Andre, H. Rugo · Institut Gustave Roussy
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  51. Abstract 97882026-09-04 · 15:30 CT · Arie Crown Theater
    Long-term follow-up of Tecentriq neoadjuvant for NSCLC: IMpower-514
    R. Herbst, M. Reck, P. Schmid, et al. · University of Chicago
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  52. Abstract 92812026-09-04 · 14:00 CT · E450
    DESTINY-Breast-312: Enhertu (trastuzumab deruxtecan) 1L in NSCLC
    C. Robert, R. Herbst, S. Antonia, et al. · Johns Hopkins Kimmel Cancer Center
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  53. Abstract 96712026-09-02 · 19:15 CT · S100A
    Long-term follow-up of Tagrisso maintenance for NSCLC: FLAURA-177
    J. Brahmer, H. Borghaei, H. Rugo · Memorial Sloan Kettering Cancer Center
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  54. Abstract 97612026-09-05 · 14:30 CT · Hall B1
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-689 study)
    H. Rugo, C. Robert, G. Curigliano · Massachusetts General Hospital
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
© 2026 American Society of Clinical Oncology · Citations follow JCO supplement format:J Clin Oncol 44, 2026 (suppl 17; abstr XXXX). Demo mock.